DoubleChecks

What was claimed

The largest human study on Ivermectin + Mebendazole for cancer is peer-reviewed and shows 84.4% clinical benefit (32.8% complete remission, 15.6% tumor regression, 36.1% stabilization). They don't want cures, they want customers

Our verdict

Needs caution

The study itself explicitly states findings are 'hypothesis-generating' and should not be interpreted as definitive. The design is observational with self-reported outcomes, selection bias potential, and uncontrolled confounding. Many patients also received concurrent conventional therapies (27.9% chemotherapy, 21.3% radiation, 19.7% surgery). This is a broad assertion about the motives of unspecified actors and is not tied to verifiable evidence or specific documented behavior. It reflects opinion or speculation rather than a factual claim that can be confirmed or refuted with available sources.

All 3 AI systems agree15 sources citedChecked Aug 17, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

These results definitively demonstrate efficacy of ivermectin and mebendazole for cancer treatment

Misleading92%
1 AI checked

They don't want cures, they want customers.

Can’t verify52%
All 3 AIs agree

The study represents the largest human study on this combination

Verified90%
1 AI checked

The largest human study on Ivermectin + Mebendazole for cancer is peer-reviewed and shows 84.4% clinical benefit (32.8% complete remission, 15.6% tumor regression, 36.1% stabilization).

Verified91%
4 of 6 AIs agree·ChatGPT: Misleading, Perplexity: Misleading

Shows 84.4% clinical benefit (32.8% complete remission, 15.6% tumor regression, 36.1% stabilization)

Verified98%
1 AI checked

Verified against 15 sources

sanarelab.sciencesanarelab.sciencecanadahealthalliance.orgtwc.healthpubmed.ncbi.nlm.nih.govyahoo.comjillcarnahan.comexplore.openaire.eux.comtherealfacthunter.combreitbart.comsciencebasedmedicine.orgpmc.ncbi.nlm.nih.govfagronacademy.uspccarx.com

Detailed Analysis

The numerical description of the study’s reported outcomes is largely accurate, but it omits key methodological limitations that affect how the results should be interpreted. The additional statement about motives and “customers” is an unsubstantiated opinion, not a factual claim supported by evidence.

Why this verdict

  • The numerical description of the study’s reported outcomes is largely accurate, but it omits key methodological limitations that affect how the results should be interpreted.
  • The additional statement about motives and “customers” is an unsubstantiated opinion, not a factual claim supported by evidence.

Claims checked

This 84.4% clinical benefit constitutes reliable evidence that Ivermectin + Mebendazole cure or effectively treat cancer

Misleading90%
Multiple expert analyses emphasize that the study is an uncontrolled, self‑reported observational cohort with no radiographic confirmation, substantial loss to follow-up, and major risk of bias, so it cannot demonstrate efficacy or cures.[6] [10] [12] They state that this evidence is hypothesis‑generating only and does not establish that the drugs treat or cure cancer.[2] [7] [12]

This claim may mislead readers without added context.

They don't want cures, they want customers

Can’t verify80%
This is a broad assertion about the motives of unspecified actors and is not tied to verifiable evidence or specific documented behavior. It reflects opinion or speculation rather than a factual claim that can be confirmed or refuted with available sources.

The largest human study on Ivermectin + Mebendazole for cancer is peer-reviewed

Verified90%
A 2026 observational cohort study titled "Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer" was published in the peer-reviewed journal Anticancer Research and is described by multiple sources as the largest human study of this combination in cancer to date.[5] [8] [11]

What other AI think

The statistical claims about the study are accurate, and it is peer-reviewed and published. However, the statement omits critical methodological limitations that fundamentally change how these results should be interpreted. The final claim about pharmaceutical motivations is an unverifiable conspiracy assertion that goes beyond what the evidence supports.

Why this verdict

  • The statistical claims about the study are accurate, and it is peer-reviewed and published.
  • However, the statement omits critical methodological limitations that fundamentally change how these results should be interpreted.
  • The final claim about pharmaceutical motivations is an unverifiable conspiracy assertion that goes beyond what the evidence supports.

Claims checked

These results definitively demonstrate efficacy of ivermectin and mebendazole for cancer treatment

Misleading92%
The study itself explicitly states findings are 'hypothesis-generating' and should not be interpreted as definitive. The design is observational with self-reported outcomes, selection bias potential, and uncontrolled confounding. Many patients also received concurrent conventional therapies (27.9% chemotherapy, 21.3% radiation, 19.7% surgery).

This claim may mislead readers without added context.

They don't want cures, they want customers

Can’t verify30%
This is a conspiratorial claim about pharmaceutical industry motivations that cannot be verified or falsified through evidence. It represents an interpretive assertion rather than a factual claim about the study itself.

The study represents the largest human study on this combination

Verified90%
Multiple sources confirm this is the largest peer-reviewed human study on ivermectin and mebendazole for cancer (n=197 enrolled, 122 completed follow-up).
The numeric outcomes (84.4% CBR; 32.8% NED; 15.6% regression; 36.1% stable disease) match a recently published prospective observational cohort. However the study is a self‑reported, nonrandomized real‑world cohort (and an Expression of Concern has been issued), so presenting it as definitive evidence or implying clear intent by unspecified parties is misleading.

Why this verdict

  • The numeric outcomes (84.4% CBR; 32.8% NED; 15.6% regression; 36.1% stable disease) match a recently published prospective observational cohort.
  • However the study is a self‑reported, nonrandomized real‑world cohort (and an Expression of Concern has been issued), so presenting it as definitive evidence or implying clear intent by unspecified parties is misleading.

Claims checked

The largest human study on Ivermectin + Mebendazole for cancer is peer-reviewed and shows 84.4% clinical benefit (32.8% complete remission, 15.6% tumor regression, 36.1% stabilization).

Misleading88%
A prospective observational cohort reporting those exact percentages was published in Anticancer Research and is available on PubMed, but its outcomes are self‑reported, nonrandomized, and the journal has issued an Expression of Concern; calling it the definitive or ‘largest’ controlled human trial overstates its strength and reliability.

This claim may mislead readers without added context.

They don't want cures, they want customers.

Can’t verify45%
This is an attribution of motive rather than a factual, testable claim and cannot be verified from the study or public evidence.

Share this result

Try DoubleChecks